leader pt
believ sarepta higher efficaci top-lin
data suggest dystrophin express like greater fiber
intens posit fiber togeth
lower dose believ sarepta broad therapeut
window take major market share
rais pt clear dmd gene therapi leadership sarepta dmd gene
therapi posit first market take major share
preval popul us expand intern
signific lead base proprietari analysi believ investor
underappreci magnitud sarepta best-in-class efficaci compar
cover david rising believ significantli higher
dose limit abil increas efficaci continu
carri signific safeti risk price sarepta dmd gene therapi
net long-term market share us/eu yoa
magnitud efficaci differ least wider headlin suggest
use proprietari approach analyz efficaci data believ
micro-dystrophin express actual closer versu
report fiber intens compar sarepta
respect base calcul compar micro-dystrophin
express half much full length dystrophin versu sarepta
believ cut report express level half present fiber
intens level estim baselin month intens level base
percent posit fiber three high dose cohort patient base convers
sarepta manag believ high dose actual sarepta
dose use ddpcr highlight magnitud viru
deliv minim efficaci thu overal believ sarepta
wide margin efficaci compar much lower dose
safeti keep increas dose suggest limit abil
compet initi reaction present focus two patient
admit hospit gi renal complic advers event
valid evid suggest could possibl induc
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
unpredict immun respons especi high dose
safe babi sma dose lower dose see
issu coupl limit efficaci construct significantli limit
abil compet
magnitud efficaci safeti differenti continu benefit
see move higher next week investor consolid
posit confirm superior posit sarepta see two key
issu drive sarepta next month first safeti issu
report mid-august believ investor assum sarepta
success dose patient pivot cohort last patient dose
around june second manag abil deliv commerci drug
suppli patient expect dose assum manag
deliv suppli believ final remain overhang relat
manufactur lift final head function data
key catalyst random data cohort
overal expect manag capit superior efficaci safeti
continu develop commerci suppli prepar launch
current act financi advisor inc
respect definit merger agreement acquir array
biopharma inc array announc june agreement subject
consumm tender offer share array requir regulatori
approv customari close condit report inform
provid herein also intend provid advic respect tender
offer ii serv endors tender offer iii result
procur withhold revoc tender exchang
action secur holder agre pay fee
financi servic includ transact fee conting upon
consumm transact pleas refer note end report
act financi advisor inc relat
agreement glaxosmithklin plc glaxo creat global consum
healthcar compani contribut consum healthcar
busi glaxo exist consum healthcar busi announc
decemb propos joint ventur subject customari close
condit includ regulatori approv agre pay fee morgan
stanley servic includ transact fee conting upon
consumm propos transact pleas refer note end
report
increas sarepta share dmd gene therapi market key driver
valuat chang exhibit revenu dmd gene therapi reach
total revenu compar previous
respect continu use risk-adjust late launch date
termin growth rate decreas discount rate remain
total revenu increas drive increas
pt
superior safeti profil sarepta micro-dystrophin construct packag
believ reduc immune-medi toxic report solid
bioscienc first report toxic phi/ii trial test
nonambulatori ambulatori dmd patient yoa start dose
vg/kg know solid titer dose thu compar dose
uncertain one patient experienc compliment activ requir eculizumab
report micro-dystrophin express escal dose
vg/kg recent report gi infect platelet count declin increas liver
enzym two time upper limit normal report drug relat
reaction includ gi disord decreas appetit infect renal
disord one patient experienc sae relat nausea vomit
requir hospit admiss result paus enrol anoth patient
experienc sae relat acut renal injuri mediat compliment activ
also requir admiss intens care unit
clinic trial includ exclus criteria relat neutral antibodi
question test alon predict patient
exagger immun respons dr jame wilson expert field resign
scientif advisori board rais dose concern
regard dr wilson publish pre-clin studi concurr resign
suggest vg/kg variant caus acut system
inflamm coagul defect hepat toxic nhp inflammatori
respons univers among nhp unpublish observ suggest
newborn primat less suscept system inflamm compar older
anim one nhp euthan earli base sever symptom
suggest anim experienc shock hemorrhag edema found
lung gi tract liver suggest acut immun respons base
preclin clinic data believ pretreat addit screen
necessari becom viabl approach deliv micro-dystrophin
sma
zolgensma base gene therapi design treat patient spinal muscular
atrophi recent approv patient yoa carri box warm
regard acut seriou liver injuri novarti cover mark purcel report low
level antibodi patient month age on-going studi
box warn suggest could caus immun respons lead liver
approach compar efficaci sarepta report posit muscl fiber
month compar month vg/kg suggest
superior transduct efficaci compar base limit patient specif
data present abl determin age correl
percentag viabl muscl cell end present includ
back-up slide describ mean fiber intens three patient includ high
dose cohort extract data determin mean fiber intens exhibit
data suggest variabl intens patient reduc overal mean
compar sarepta
beyond transduct effici safeti signal investor continu debat
compar express micro-dystrophin base convers sarepta
manag sourc rel valu propos one specul approach
compar express level exhibit sarepta collabor academ group
report variabl dystrophin level healthi individu wide
accept literatur conclud one sampl averag
dystrophin rang believ reason estim
averag express dystrophin striat muscl assum sarepta load
total protein western blot base sec file know molecular
weight dystrophen base assumpt abl predict
total amount micro-dystrophin compar approxim
fmol full length dystrophin low dose normal dystrophin
express equal fmol/mg normal dystrophin abl convert
fmol/ug assum extract total protein yield
approxim fmol full length dystrophin signific find
impli normal dystrophin compar lower end
predict dystrophin level report fmol micro-dystrophin
significantli lower sarepta three patient fmol nationwid
fmol sarepta base data believ sarepta gene therapi
produc significantli micro-dystrophin along compar
rel level lower end full-length dystrophin concentr
toxic nonhuman primat piglet follow high-dos intraven
administr adeno-associ viru vector express smn
schnell fj frank fletcher johnsen rd wilton sd challeng interpret
dystrophin content western blot us neurolog
long-term prospect sarepta dmd franchis drive valu
long-term prospect sarepta dmd franchis
pt deriv dcf use discount rate
termin growth beyond valu sarepta dmd franchis
bull scenario assum exondi achiev rapid launch sale
taper peak penetr achiev also assum aggress sale
exon approv well signific updat gene therapi
base case scenario assum continu strength exondi well
approv golodirsen camisersen risk-adjust dmd
gene therapi total revenu
assum lower peak penetr exondi approv golodirsen
modest sale approv camisersen downstream eros usag
includ revenu altern mutat
overweight thesi base
strong initi dmd genetherapi data
manag abil captur signific
market share dmd gene therapi
product gene therapi remain riski
believ initi data derisk program
provid signific upsid potenti
base busi exon skip drug
pipelin larg divers offer lgmd
potenti upsid driver
time market clinic success
risk achiev price
updat dmd gene therapi
program includ risk relat
manufactur on-going regulatori
failur secur addit regulatori
approv obtain reimburs could
data competitor compani could
either posit neg impact
sarepta posit dmd market
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
